Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01341171 · ClinicalTrials.gov registry record
The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins
A clinical trial, sponsored by University of Vermont.
- Completed
- Registry status
- 30
- Enrollment target
NCT01341171: Completed study, sponsored by University of Vermont.
NCT01341171 is a clinical trial that has completed, run by University of Vermont. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01341171 has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Single phlebotomy study involving women receiving tamoxifen or aromatase inhibitor therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-08 |
| Est. Completion | 2018-10 |
What the finished NCT01341171 record still lists
NCT01341171 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01341171 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01341171 about?
NCT01341171 is a clinical study titled "The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins". Single phlebotomy study involving women receiving tamoxifen or aromatase inhibitor therapy.
What is the current status of trial NCT01341171?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2009-08. Estimated completion is 2018-10.
Who is sponsoring clinical trial NCT01341171?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia